Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
The company patent portfolio for Teika Pharmaceutical Co. Ltd. currently shows 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating a balanced range of technical subject matter. SCHLIENTZ, NATHAN W is the busiest examiner for the portfolio, currently overseeing 1 busiest examiner pending office action. This spread of 2 pending office actions across 2 distinct examiners suggests that the company is not facing a bottleneck with any single individual.
For a practitioner, the use of 2 distinct art units means that the prosecution strategy must be tailored to different technical standards within the Biotechnology & Pharmaceuticals field. Because 1 busiest examiner pending action is the maximum handled by any one person, the portfolio's progress is not overly dependent on SCHLIENTZ, NATHAN W. This distribution across 2 distinct art units provides a broader base for the company's intellectual property strategy. Managing 2 pending office actions requires coordination to ensure consistent messaging across the different examiners. This profile for Teika Pharmaceutical Co. Ltd. reflects a diversified approach to its ongoing patent prosecution efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLIENTZ, NATHAN W | 1 | 41.3% | -18.8% |
| NGUYEN, NGOC-ANH THI | 1 | 30.3% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704631 | COSMETIC FOR HAIR GROWTH, COSMETIC RAW MATERIAL AND COSMETIC, AND METHOD FOR PRODUCING THE SAME | NGUYEN, NGOC-ANH THI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704631 | COSMETIC FOR HAIR GROWTH, COSMETIC RAW MATERIAL AND COSMETIC, AND METHOD FOR PRODUCING THE SAME | NGUYEN, NGOC-ANH THI | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18966037 | RIFAMYCIN OPHTHALMIC COMPOSITION AND USE THEREOF | SCHLIENTZ, NATHAN W | 1616 | §102§103§112DP | Non-Final OA | — | Pending | Dec 02, 2024 |
| 18704631 | COSMETIC FOR HAIR GROWTH, COSMETIC RAW MATERIAL AND COSMETIC, AND METHOD FOR PRODUCING THE SAME | NGUYEN, NGOC-ANH THI | 1615 | §101§102§103 | Non-Final OA | — | Pending | Apr 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTeika Pharmaceutical Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Nathan W Schlientz has the most, with 1 of Teika Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
